Please login to the form below

Not currently logged in
Email:
Password:

epoetin alfa

This page shows the latest epoetin alfa news and features for those working in and with pharma, biotech and healthcare.

BMS’s Reblozyl meets primary endpoint in myelodysplastic syndromes phase 3 trial

BMS’s Reblozyl meets primary endpoint in myelodysplastic syndromes phase 3 trial

COMMAND is a phase 3, open-label, randomised trial evaluating the efficacy and safety of Reblozyl versus epoetin alfa.

Latest news

More from news
Approximately 1 fully matching, plus 40 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Langland

Langland, a Publicis Health company, is the only health communications agency that thinks further across Clinical Trial Experience, Medical Strategy...

Latest intelligence

World Cancer Day 2023 – closing the gaps in cancer care to give more patients access to life-changing medicines
Great Expectations – exploring the counterpoint between advances in oncology and the challenges of ensuring life-changing medicines reach patients...
Strategic behaviour
Strong strategising depends on your colleagues’ behaviour...
Pharmaceutical Marketing Strategies For The Digital Age
In the digital age, a strong digital marketing strategy is crucial for businesses, especially in the highly competitive and complex pharmaceutical industry. There are key trends shaping pharmaceutical marketing, such...